Wu Jiali, Zhang Kaoyuan, Liao Yan, Yang Chener, Ge Jingyao, Wu Chenchen, Yu Bo, Zhong Weilong, Shao Yong, Dou Xia
Department of Dermatology, Peking University Shenzhen Hospital, Institute of Dermatology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China.
Shenzhen Key Laboratory for Translational Medicine of Dermatology, Biomedical Research Institute, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Guangdong Province, Shenzhen, China.
Immun Inflamm Dis. 2025 Sep;13(9):e70263. doi: 10.1002/iid3.70263.
The available evidence increasingly indicates that SERPINB3/4 plays a pivotal role in the progression of inflammatory diseases and may serve as a valuable biomarker for atopic dermatitis and psoriasis. However, the expression of SERPINB3/4 in the serum of patients with moderate-to-severe prurigo nodularis (PN) remains poorly understood.
To find a promising biomarker for monitoring the severity and activity of moderate-to-severe PN patients.
A total of 41 patients with moderate-to-severe PN and 20 healthy subjects were included in the study. Enzyme-linked immunosorbent assay (ELISA) was performed to determine serum SERPINB3/4 expression. Cutaneous SERPINB3/4 expression was evaluated by immunohistochemistry (IHC). Serum SERPINB3/4 levels were correlated with PN disease severity and activity scores, hematological parameters, and systemic inflammatory markers.
SERPINB3/4 expression was found to be significantly increased in the serum and lesions of PN in comparison to healthy subjects. In patients with PN, the expression of serum SERPINB3/4 was significantly elevated in subjects with higher investigator global assessment (IGA) scores, while exhibiting a notable decline in patients with higher pruritus numeric rating scale (P-NRS) scores. Positive correlations were observed between serum SERPINB3/4 levels and peripheral eosinophil count, eosinophil ratio, and eosinophil-to-lymphocyte ratio (ELR) in patients with PN.
SERPINB3/4 expression was increased in PN sera and lesions. Serum SERPINB3/4 expression was positively correlated with PN severity and peripheral eosinophil-related parameters, suggesting its potential as a promising biomarker for PN.
现有证据越来越多地表明，丝氨酸蛋白酶抑制剂B3/4（SERPINB3/4）在炎症性疾病的进展中起关键作用，并且可能作为特应性皮炎和银屑病的有价值生物标志物。然而，中重度结节性痒疹（PN）患者血清中SERPINB3/4的表达仍知之甚少。
寻找一种有前景的生物标志物来监测中重度PN患者的严重程度和活动度。
本研究共纳入41例中重度PN患者和20名健康受试者。采用酶联免疫吸附测定（ELISA）法测定血清SERPINB3/4表达。通过免疫组织化学（IHC）评估皮肤SERPINB3/4表达。血清SERPINB3/4水平与PN疾病严重程度和活动度评分、血液学参数及全身炎症标志物相关。
与健康受试者相比，发现PN患者血清和皮损中SERPINB3/4表达显著增加。在PN患者中，研究者整体评估（IGA）评分较高的受试者血清SERPINB3/4表达显著升高，而瘙痒数字评定量表（P-NRS）评分较高的患者则显著下降。PN患者血清SERPINB3/4水平与外周血嗜酸性粒细胞计数、嗜酸性粒细胞比例及嗜酸性粒细胞与淋巴细胞比值（ELR）之间存在正相关。
PN患者血清和皮损中SERPINB3/4表达增加。血清SERPINB3/4表达与PN严重程度及外周血嗜酸性粒细胞相关参数呈正相关，提示其有望成为PN的生物标志物。
